Takeda and Astellas key firms in advancing early gene therapy research in Japan

18 September 2024

Gene therapy research in Japan has gained significant momentum due to the SAKIGAKE designation system and government-led initiatives like the “Project for Regenerative/Cellular Medicine and Gene Therapies” to accelerate research and development (R&D) to create new technologies for gene/cell therapy.

In advancing early gene therapy research in Japan, Takeda (TYO: 4502) and Astellas Pharma (TYO: 4503) currently stand as key firms leading the overall pre-clinical (PC) development with four candidates each and contributing 57% of PC gene therapy research in the country, says pharma analytics company GlobalData.

According to GlobalData’s Pharmaceutical Intelligence Center, as of September 16, 2024, in Japan there are 14 gene therapies in PC stage of development targeting eight different therapy areas with a significant focus on oncology, ophthalmology, hematological disorders, and the central nervous system (CNS).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK